Do you or your patients have questions about the interchangeability of generic and brand name drugs?
We invite you to join in this independent learning activity featuring Dr. Jake Thiessen, who brings vast experience in bioequivalence and the implications in patient care.
In this presentation, Dr. Thiessen showcases the scientific principles and evidence supporting Health Canada’s standards and testing criteria used to establish bioequivalence, a measure that applies to both generic and brand name drugs.
By taking part in this program, you will be better prepared to answer your patient’s questions about the interchangeability of generic and brand name drugs; and make informed prescribing decisions that can lead to more effective healthcare spending.
Following the one-hour video presentation you will have the opportunity to participate in an online discussion group with your fellow colleagues.
Join the program
To view this presentation and take part in the discussion you must first register. If you already have an account or are returning to complete or review the program, please log in to your account to continue.
Jake J. Thiessen, PhD
- Founding Director, Health Sciences Campus & School of Pharmacy, University of Waterloo
- Professor Emeritus, Leslie Dan Faculty of Pharmacy, University of Toronto
- Past Chair, Scientific Advisory Committee on Bioavailability and Bioequivalence, Health Canada
- Past Chair, Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology, Health Canada
Dr. Thiessen is a former professor, associate dean and current professor emeritus at the Leslie Dan Faculty of Pharmacy, University of Toronto. Following 33 years at the University of Toronto, he spent six years at the University of Waterloo where he had strategic responsibility for the development of a new health science campus along with Canada’s tenth school of pharmacy. His broad experience has included international projects in Taiwan, Sudan, Nigeria, and the Caribbean. He has held numerous national academic positions, including President of the Canadian Council for Accreditation of Pharmacy Programs.
Provincially, he has been Chair of the Drug Quality and Therapeutics Committee, and most recently served the Ontario Minister of Health and Long Term Care as an independent reviewer of the under-dosing of oncology medicines discovered in Ontario.
Federally, he has served Health Canada for nearly 25 years in positions that included Chair of the Scientific Advisory Committee on Bioavailability and Bioequivalence, and the Chair of the Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.
- To better understand the role of Health Canada
- To understand the scientific principles and evidence supporting Health Canada’s approval of generic medicines
- To understand the growing body of objective clinical evidence supporting the trust in generic medicines
Invite a colleague
Help empower physicians and pharmacists in your professional network to answer common questions about generics.
* = Required